Combined Pituitary Hormone Deficiencies, Genetic Form

Mendelian MONDO:0018762 Pathograph 15 non-acquired pituitary hormone deficiency hereditary disease

Combined pituitary hormone deficiencies, genetic form is congenital hypopituitarism in which germline defects affecting pituitary organogenesis, midline patterning, or anterior pituitary lineage specification cause deficiency of growth hormone plus at least one additional pituitary hormone. The phenotype is genetically heterogeneous and may include GH, TSH, ACTH, gonadotropin, prolactin, and posterior pituitary hormone involvement, with severity and progression varying by gene and structural pituitary findings.

Ask OpenScientist

Ask a research question about Combined Pituitary Hormone Deficiencies, Genetic Form. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Definitions
3
Pathophys.
14
Phenotypes
15
Pathograph
4
Genes
5
Treatments
1
Deep Research
📘

Definitions

1
Multiple pituitary hormone deficiency definition
The defining clinical feature is deficiency of two or more pituitary hormones. In congenital CPHD cohorts, growth hormone deficiency with at least one additional pituitary hormone deficit is a common operational definition.
OTHER
Show evidence (2 references)
DOI:10.32641/andespediatr.v94i6.4680 SUPPORT Human Clinical
"The deficiency of two or more pituitary hormones is called multiple pituitary hormone deficiencies (MPHD)."
This directly defines multiple pituitary hormone deficiency as a multi-axis pituitary hormone deficiency state.
DOI:10.1530/ec-24-0217 SUPPORT Human Clinical
"In total, 34 children (12 girls) with congenital CPHD (growth hormone (GH) deficiency and impaired secretion of at least one other pituitary hormone) treated with GH in our center were enrolled in the study."
This pediatric congenital CPHD cohort operationalizes congenital CPHD as GH deficiency plus impaired secretion of at least one other pituitary hormone.
⚙

Pathophysiology

3
Developmental Gene Disruption
Germline variants in pituitary-development, midline-patterning, and lineage-specification genes disrupt pituitary morphogenesis or endocrine cell differentiation. This upstream genetic heterogeneity explains why affected individuals can have isolated anterior pituitary cell-lineage failure, structural pituitary malformations, or broader extrapituitary phenotypes.
POU1F1 link PROP1 link HESX1 link GLI2 link LHX4 link
pituitary gland development link ↓ DECREASED endocrine system development link ⚠ ABNORMAL
hypothalamus-pituitary axis link pituitary gland link
Downstream
Anterior Pituitary Endocrine-Axis Failure Impaired pituitary development reduces the differentiated hormone-producing cell populations that normally maintain multiple anterior pituitary axes.
Structural Pituitary Malformation Developmental-gene disruption may also produce visible pituitary MRI malformations, including anterior pituitary hypoplasia and ectopic posterior pituitary findings.
Show evidence (2 references)
DOI:10.6065/apem.2448008.004 SUPPORT Human Clinical
"Pathogenic variants in POU1F1, GLI2, HESX1, TBC1D32, and ROBO1 were found in 5 (19.2%)."
This cohort supports heterogeneous developmental gene involvement in childhood-onset congenital CPHD.
DOI:10.1186/s13073-024-01347-y SUPPORT Model Organism
"Of the 209 knockout mouse lines, we identified 51 that have embryonic pituitary malformations."
This mouse phenotyping screen supports a broad developmental-gene mechanism for congenital hypopituitarism and CPHD.
Anterior Pituitary Endocrine-Axis Failure
Reduced function of multiple anterior pituitary cell lineages causes the core endocrine phenotype: GH deficiency, central hypothyroidism, ACTH deficiency or central adrenal insufficiency, hypogonadotropic hypogonadism, and prolactin deficiency in variable combinations.
somatotroph link thyrotroph link corticotroph link mammotroph link gonadotroph link
endocrine process link ↓ DECREASED
adenohypophysis link
Show evidence (2 references)
DOI:10.32641/andespediatr.v94i6.4680 SUPPORT Human Clinical
"At admission, GH deficiency was found in 88.9% of the cases, TSH deficiency in 77.8%, ACTH deficiency in 33.3%, FSH/LH deficiency in 22.2%, and PRL deficiency in 17.8%."
This cohort quantifies multi-axis anterior pituitary hormone deficiency.
DOI:10.1530/ec-24-0217 SUPPORT Human Clinical
"Of them, 30 had central adrenal insufficiency, 27 had central hypothyroidism, ten had hypogonadotropic hypogonadism, and three had central diabetes insipidus."
This congenital CPHD cohort supports central endocrine-axis failure across adrenal, thyroid, gonadal, and posterior pituitary axes.
Structural Pituitary Malformation
Many genetic CPHD cases have pituitary MRI abnormalities, including anterior pituitary hypoplasia, ectopic posterior pituitary, or other midline structural defects that correlate with the number of hormone deficiencies.
pituitary gland development link ⚠ ABNORMAL
pituitary gland link neurohypophysis link
Show evidence (1 reference)
DOI:10.6065/apem.2448008.004 SUPPORT Human Clinical
"Brain MRI abnormalities correlated with a higher number of hormone deficiencies (P for trend 0.049) and were present in 33 patients (80.5%)."
This supports structural pituitary or brain MRI abnormalities as common and clinically meaningful in congenital CPHD.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Combined Pituitary Hormone Deficiencies, Genetic Form Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

14
Digestive 1
Neonatal Cholestasis Cholestasis (HP:0001396)
Onset: NEONATAL
Show evidence (1 reference)
DOI:10.3390/ijms241210114 SUPPORT Human Clinical
"The many clinical signs and symptoms include hypoglycaemia, neonatal cholestasis and micropenis."
The review lists neonatal cholestasis among clinical signs and symptoms of neonatal isolated and combined GHD.
Endocrine 5
Secondary Growth Hormone Deficiency Secondary growth hormone deficiency (HP:0008240)
Show evidence (1 reference)
DOI:10.6065/apem.2448008.004 SUPPORT Human Clinical
"Growth hormone deficiency (GHD) was prevalent in 42 (97.7%), and 33 (76.7%) had 3 or more hormone deficiencies."
The congenital CPHD cohort reports GH deficiency in nearly all affected patients.
Hypogonadotropic Hypogonadism Hypogonadotropic hypogonadism (HP:0000044)
Show evidence (1 reference)
DOI:10.1530/ec-24-0217 SUPPORT Human Clinical
"Of them, 30 had central adrenal insufficiency, 27 had central hypothyroidism, ten had hypogonadotropic hypogonadism, and three had central diabetes insipidus."
This congenital CPHD cohort directly reports hypogonadotropic hypogonadism.
Central Diabetes Insipidus Central diabetes insipidus (HP:0000863)
Show evidence (1 reference)
DOI:10.1530/ec-24-0217 SUPPORT Human Clinical
"Of them, 30 had central adrenal insufficiency, 27 had central hypothyroidism, ten had hypogonadotropic hypogonadism, and three had central diabetes insipidus."
This congenital CPHD cohort reports central diabetes insipidus as one of the observed hormone-deficiency phenotypes.
Anterior Pituitary Hypoplasia Anterior pituitary hypoplasia (HP:0010627)
Show evidence (1 reference)
DOI:10.3390/ijms26062406 SUPPORT Human Clinical
"All six patients exhibited anterior pituitary hypoplasia on brain magnetic resonance imaging and presented with TSH, GH, and PRL deficiencies."
This POU1F1 cohort directly links anterior pituitary hypoplasia with combined anterior pituitary hormone deficiencies.
Interrupted Pituitary Stalk Interrupted pituitary stalk (HP:0034978)
Show evidence (1 reference)
DOI:10.1007/s42000-023-00510-1 SUPPORT Human Clinical
"MRI of the pituitary gland in CPHD-PROP1 revealed a small pituitary gland (21 cases), pituitary gland enlargement (eight cases), and one pituitary stalk interruption and posterior lobe ectopy, while it was normal in nine cases."
This PROP1 CPHD cohort describes pituitary stalk interruption and posterior lobe ectopy among MRI findings.
Genitourinary 1
Micropenis Micropenis (HP:0000054)
Onset: NEONATAL
Show evidence (1 reference)
DOI:10.3390/ijms241210114 SUPPORT Human Clinical
"The many clinical signs and symptoms include hypoglycaemia, neonatal cholestasis and micropenis."
The neonatal management review lists micropenis among signs and symptoms.
Growth 1
Short Stature Short stature (HP:0004322)
Show evidence (1 reference)
DOI:10.6065/apem.2448008.004 SUPPORT Human Clinical
"Short stature was the most frequent (37.2%) initial presentation, and mean height z-score was -2.4."
This cohort identifies short stature as the most frequent initial presentation.
Other 6
Anterior Hypopituitarism Anterior hypopituitarism (HP:0000830)
Show evidence (1 reference)
DOI:10.32641/andespediatr.v94i6.4680 SUPPORT Human Clinical
"The deficiency of two or more pituitary hormones is called multiple pituitary hormone deficiencies (MPHD)."
This definition supports anterior hypopituitarism as the core disease phenotype when multiple pituitary axes are deficient.
Central Hypothyroidism Central hypothyroidism (HP:0011787)
Show evidence (1 reference)
DOI:10.1530/ec-24-0217 SUPPORT Human Clinical
"Of them, 30 had central adrenal insufficiency, 27 had central hypothyroidism, ten had hypogonadotropic hypogonadism, and three had central diabetes insipidus."
This cohort directly reports central hypothyroidism in congenital CPHD.
Adrenocorticotropic Hormone Deficiency Adrenocorticotropic hormone deficiency (HP:0011748)
Show evidence (1 reference)
DOI:10.32641/andespediatr.v94i6.4680 SUPPORT Human Clinical
"At admission, GH deficiency was found in 88.9% of the cases, TSH deficiency in 77.8%, ACTH deficiency in 33.3%, FSH/LH deficiency in 22.2%, and PRL deficiency in 17.8%."
This MPHD cohort reports ACTH deficiency among affected patients.
Prolactin Deficiency Reduced circulating prolactin concentration (HP:0008202)
Show evidence (1 reference)
DOI:10.32641/andespediatr.v94i6.4680 SUPPORT Human Clinical
"At admission, GH deficiency was found in 88.9% of the cases, TSH deficiency in 77.8%, ACTH deficiency in 33.3%, FSH/LH deficiency in 22.2%, and PRL deficiency in 17.8%."
This MPHD cohort reports PRL deficiency as one component of the multi-axis endocrine phenotype.
Neonatal Hypoglycemia Neonatal hypoglycemia (HP:0001998)
Onset: NEONATAL
Show evidence (1 reference)
DOI:10.3390/ijms241210114 SUPPORT Human Clinical
"The many clinical signs and symptoms include hypoglycaemia, neonatal cholestasis and micropenis."
This neonatal GHD/combined GHD review lists hypoglycemia among clinical signs and symptoms.
Ectopic Posterior Pituitary Ectopic posterior pituitary (HP:0011755)
Show evidence (1 reference)
DOI:10.3390/children12030364 SUPPORT Human Clinical
"Brain magnetic resonance imaging (MRI) revealed pituitary hypoplasia, ectopic posterior pituitary gland, and small sella turcica in all probands."
This LHX4 report directly describes ectopic posterior pituitary in MPHD probands.
🧬

Genetic Associations

4
Heterogeneous developmental gene variants
Show evidence (2 references)
DOI:10.6065/apem.2448008.004 SUPPORT Human Clinical
"Pathogenic variants in POU1F1, GLI2, HESX1, TBC1D32, and ROBO1 were found in 5 (19.2%)."
This congenital CPHD cohort identifies pathogenic variants in multiple developmental genes.
DOI:10.1530/ec-24-0217 SUPPORT Human Clinical
"The remaining 6 children had causative genetic variants in the GLI2, PROP1, POU1F1, TBX3, PMM2, and GNAO1 genes, respectively."
This independent congenital CPHD cohort supports a heterogeneous causal gene spectrum including PROP1, POU1F1, GLI2, and candidate genes.
PROP1 pathogenic variants
Autosomal recessive inheritance
Show evidence (5 references)
DOI:10.1007/s42000-023-00510-1 SUPPORT Human Clinical
"The most commonly identified genetic cause of combined pituitary hormone deficiency (CPHD) is PROP1 gene mutations."
This PROP1-focused pediatric cohort identifies PROP1 mutations as the most commonly identified genetic cause of CPHD.
DOI:10.1530/ec-24-0217 SUPPORT Human Clinical
"The remaining 6 children had causative genetic variants in the GLI2, PROP1, POU1F1, TBX3, PMM2, and GNAO1 genes, respectively."
This congenital CPHD cohort includes a child with causative PROP1 variants among genetically solved cases.
DOI:10.1007/s42000-023-00510-1 SUPPORT Human Clinical
"significantly lower prolactin concentrations (128 vs. 416.3"
This comparison supports lower prolactin as a PROP1-associated genotype-phenotype feature.
+ 2 more references
POU1F1 pathogenic variants
Show evidence (2 references)
DOI:10.3390/ijms26062406 SUPPORT Human Clinical
"Variants in the POU1F1 gene are associated with combined pituitary hormone deficiency 1 (CPHD1), which manifests as deficiencies in growth hormone (GH), thyroid-stimulating hormone (TSH), and prolactin (PRL)."
This directly identifies POU1F1 variants as a cause of CPHD1 and names the affected hormone axes.
DOI:10.3390/ijms26062406 SUPPORT Human Clinical
"All patients were definitively diagnosed with CPHD1 caused by POU1F1 variants."
This confirms causal POU1F1 diagnoses in the reported Vietnamese CPHD1 patients.
LHX4 pathogenic variants
Autosomal dominant heterozygous LHX4-related MPHD
Show evidence (1 reference)
DOI:10.3390/children12030364 SUPPORT Human Clinical
"This study confirms that heterozygous pathogenic variants of LHX4 can cause MPHD associated with a specific neuroradiological triad of abnormalities despite incomplete penetrance and variable phenotype."
This supports heterozygous LHX4 pathogenic variants as a cause of MPHD with variable phenotype.
💊

Treatments

5
Pituitary Hormone Replacement
Action: Pharmacotherapy NCIT:C15986
Treatment is tailored to the deficient axes and generally consists of replacement of missing pituitary target hormones, with attention to interactions between replacement therapies.
Mechanism Target:
MODULATES Anterior Pituitary Endocrine-Axis Failure — Replacement therapy bypasses deficient endogenous pituitary-axis hormone output and treats downstream endocrine failure.
Show evidence (1 reference)
DOI:10.3390/jcm13206161 SUPPORT Human Clinical
"Hormone replacement therapy is the mainstay of treatment, significantly improving patients’ quality of life."
This review supports hormone replacement as the main treatment for hypopituitarism.
Human Growth Hormone Replacement Therapy
Action: human growth hormone replacement therapy MAXO:0000780
Recombinant human growth hormone is used for GH deficiency to reduce hypoglycemia risk in early disease and improve growth outcomes.
Target Phenotypes: secondary growth hormone deficiency ↗
Show evidence (2 references)
DOI:10.3390/ijms241210114 SUPPORT Human Clinical
"Early GH replacement therapy leads to more positive outcomes, including reduced hypoglycaemia, growth recovery, metabolic asset, and neurodevelopmental improvements."
This neonatal review supports early GH replacement for clinical outcome improvement.
DOI:10.3390/ijms26062406 SUPPORT Human Clinical
"All patients received levothyroxine and recombinant human growth hormone (rhGH) replacement therapy, leading to considerable growth."
This POU1F1 cohort reports rhGH therapy and growth response in CPHD1.
Levothyroxine Replacement
Action: Pharmacotherapy NCIT:C15986
Agent: levothyroxine ↗
Levothyroxine is used when central hypothyroidism is present; thyroid-axis replacement should be coordinated with adrenal-axis assessment.
Target Phenotypes: central hypothyroidism ↗
Show evidence (1 reference)
DOI:10.3390/ijms26062406 SUPPORT Human Clinical
"All patients received levothyroxine and recombinant human growth hormone (rhGH) replacement therapy, leading to considerable growth."
This CPHD1 cohort reports levothyroxine use alongside rhGH replacement in patients with POU1F1-related CPHD.
Hydrocortisone Replacement
Action: Pharmacotherapy NCIT:C15986
Agent: hydrocortisone ↗
Hydrocortisone or cortisol glucocorticoid replacement is used when ACTH deficiency or central adrenal insufficiency is present, reducing the risk from untreated adrenal-axis failure during illness or stress.
Mechanism Target:
MODULATES Anterior Pituitary Endocrine-Axis Failure — Glucocorticoid replacement bypasses deficient ACTH-driven cortisol production downstream of anterior pituitary endocrine-axis failure.
Target Phenotypes: adrenocorticotropic hormone deficiency ↗
Show evidence (2 references)
DOI:10.1530/ec-24-0217 SUPPORT Human Clinical
"Of them, 30 had central adrenal insufficiency, 27 had central hypothyroidism, ten had hypogonadotropic hypogonadism, and three had central diabetes insipidus."
This congenital CPHD cohort documents central adrenal insufficiency as a frequent target phenotype for glucocorticoid replacement.
DOI:10.3390/jcm13206161 SUPPORT Human Clinical
"Hormone replacement therapy is the mainstay of treatment, significantly improving patients’ quality of life."
This hypopituitarism management review supports hormone replacement as the main treatment strategy for deficient pituitary axes.
Desmopressin for Central Diabetes Insipidus
Action: Pharmacotherapy NCIT:C15986
Agent: desmopressin ↗
Desmopressin, a vasopressin analog, is used when posterior pituitary or hypothalamic involvement produces central diabetes insipidus.
Target Phenotypes: central diabetes insipidus ↗
Show evidence (1 reference)
DOI:10.1530/ec-24-0217 SUPPORT Human Clinical
"Of them, 30 had central adrenal insufficiency, 27 had central hypothyroidism, ten had hypogonadotropic hypogonadism, and three had central diabetes insipidus."
This congenital CPHD cohort documents central diabetes insipidus as a treatment target in a subset of patients.
{ }

Source YAML

click to show 
name: Combined Pituitary Hormone Deficiencies, Genetic Form
creation_date: "2026-05-10T18:40:02Z"
updated_date: "2026-05-10T19:43:53Z"
category: Mendelian
disease_term:
  preferred_term: combined pituitary hormone deficiencies, genetic form
  term:
    id: MONDO:0018762
    label: non-acquired combined pituitary hormone deficiency
parents:
- non-acquired pituitary hormone deficiency
- hereditary disease
synonyms:
- congenital combined pituitary hormone deficiency
- congenital hypopituitarism
- multiple pituitary hormone deficiency
- non-acquired combined pituitary hormone deficiency
description: >-
  Combined pituitary hormone deficiencies, genetic form is congenital
  hypopituitarism in which germline defects affecting pituitary organogenesis,
  midline patterning, or anterior pituitary lineage specification cause
  deficiency of growth hormone plus at least one additional pituitary hormone.
  The phenotype is genetically heterogeneous and may include GH, TSH, ACTH,
  gonadotropin, prolactin, and posterior pituitary hormone involvement, with
  severity and progression varying by gene and structural pituitary findings.
definitions:
- name: Multiple pituitary hormone deficiency definition
  definition_type: OTHER
  description: >-
    The defining clinical feature is deficiency of two or more pituitary
    hormones. In congenital CPHD cohorts, growth hormone deficiency with at
    least one additional pituitary hormone deficit is a common operational
    definition.
  evidence:
  - reference: DOI:10.32641/andespediatr.v94i6.4680
    reference_title: Long-term follow-up data of patients with Multiple Pituitary Hormone Deficiency
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The deficiency of two or more pituitary hormones is called multiple pituitary hormone deficiencies (MPHD)."
    explanation: >-
      This directly defines multiple pituitary hormone deficiency as a
      multi-axis pituitary hormone deficiency state.
  - reference: DOI:10.1530/ec-24-0217
    reference_title: "Etiology of combined pituitary hormone deficiency: GNAO1 as a novel candidate gene"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In total, 34 children (12 girls) with congenital CPHD (growth hormone (GH) deficiency and impaired secretion of at least one other pituitary hormone) treated with GH in our center were enrolled in the study."
    explanation: >-
      This pediatric congenital CPHD cohort operationalizes congenital CPHD as
      GH deficiency plus impaired secretion of at least one other pituitary
      hormone.
prevalence:
- population: Worldwide
  notes: >-
    Published estimates for multiple pituitary hormone deficiency are
    heterogeneous, but one long-term pediatric cohort review cites a worldwide
    prevalence of about 1 in 8,000.
  evidence:
  - reference: DOI:10.32641/andespediatr.v94i6.4680
    reference_title: Long-term follow-up data of patients with Multiple Pituitary Hormone Deficiency
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Its prevalence is estimated to be about 1/8,000 worldwide."
    explanation: >-
      This gives the prevalence estimate used here for MPHD broadly.
progression:
- phase: Longitudinal endocrine evolution
  notes: >-
    Hormone deficits may accumulate after the first diagnosis, so long-term
    surveillance of all pituitary axes is part of disease management.
  evidence:
  - reference: DOI:10.32641/andespediatr.v94i6.4680
    reference_title: Long-term follow-up data of patients with Multiple Pituitary Hormone Deficiency
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "During the follow-up, 62% of the cases added other hormone deficiencies."
    explanation: >-
      This supports progressive or evolving pituitary hormone involvement in a
      substantial fraction of patients.
- phase: Syndromic and extrapituitary involvement
  notes: >-
    Congenital genetic CPHD can include extrapituitary phenotypes, so clinical
    surveillance should not be limited to endocrine axes and pituitary MRI
    findings alone.
  evidence:
  - reference: DOI:10.6065/apem.2448008.004
    reference_title: "Clinical and genetic features of childhood-onset congenital combined pituitary hormone deficiency: a retrospective, single-center cohort study"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Extrapituitary phenotypes were identified in 31 (72.1%)."
    explanation: >-
      This congenital CPHD cohort reports frequent extrapituitary phenotypes.
pathophysiology:
- name: Developmental Gene Disruption
  description: >-
    Germline variants in pituitary-development, midline-patterning, and
    lineage-specification genes disrupt pituitary morphogenesis or endocrine
    cell differentiation. This upstream genetic heterogeneity explains why
    affected individuals can have isolated anterior pituitary cell-lineage
    failure, structural pituitary malformations, or broader extrapituitary
    phenotypes.
  genes:
  - preferred_term: POU1F1
    term:
      id: hgnc:9210
      label: POU1F1
  - preferred_term: PROP1
    term:
      id: hgnc:9455
      label: PROP1
  - preferred_term: HESX1
    term:
      id: hgnc:4877
      label: HESX1
  - preferred_term: GLI2
    term:
      id: hgnc:4318
      label: GLI2
  - preferred_term: LHX4
    term:
      id: hgnc:21734
      label: LHX4
  locations:
  - preferred_term: hypothalamus-pituitary axis
    term:
      id: UBERON:0004092
      label: hypothalamus-pituitary axis
  - preferred_term: pituitary gland
    term:
      id: UBERON:0000007
      label: pituitary gland
  biological_processes:
  - preferred_term: pituitary gland development
    term:
      id: GO:0021983
      label: pituitary gland development
    modifier: DECREASED
  - preferred_term: endocrine system development
    term:
      id: GO:0035270
      label: endocrine system development
    modifier: ABNORMAL
  evidence:
  - reference: DOI:10.6065/apem.2448008.004
    reference_title: "Clinical and genetic features of childhood-onset congenital combined pituitary hormone deficiency: a retrospective, single-center cohort study"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pathogenic variants in POU1F1, GLI2, HESX1, TBC1D32, and ROBO1 were found in 5 (19.2%)."
    explanation: >-
      This cohort supports heterogeneous developmental gene involvement in
      childhood-onset congenital CPHD.
  - reference: DOI:10.1186/s13073-024-01347-y
    reference_title: Knockout mice with pituitary malformations help identify human cases of hypopituitarism
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Of the 209 knockout mouse lines, we identified 51 that have embryonic pituitary malformations."
    explanation: >-
      This mouse phenotyping screen supports a broad developmental-gene
      mechanism for congenital hypopituitarism and CPHD.
  downstream:
  - target: Anterior Pituitary Endocrine-Axis Failure
    causal_link_type: DIRECT
    description: >-
      Impaired pituitary development reduces the differentiated
      hormone-producing cell populations that normally maintain multiple
      anterior pituitary axes.
    evidence:
    - reference: DOI:10.3390/ijms26062406
      reference_title: Identification of POU1F1 Variants in Vietnamese Patients with Combined Pituitary Hormone Deficiency
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "All six patients exhibited anterior pituitary hypoplasia on brain magnetic resonance imaging and presented with TSH, GH, and PRL deficiencies."
      explanation: >-
        This POU1F1 cohort links structural anterior pituitary hypoplasia with
        multiple anterior pituitary hormone deficiencies.
  - target: Structural Pituitary Malformation
    causal_link_type: DIRECT
    description: >-
      Developmental-gene disruption may also produce visible pituitary MRI
      malformations, including anterior pituitary hypoplasia and ectopic
      posterior pituitary findings.
    evidence:
    - reference: DOI:10.3390/children12030364
      reference_title: A Novel Missense Variant in LHX4 in Three Children with Multiple Pituitary Hormone Deficiency Belonging to Two Unrelated Families and Contribution of Additional GLI2 and IGFR1 Variant
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Brain magnetic resonance imaging (MRI) revealed pituitary hypoplasia, ectopic posterior pituitary gland, and small sella turcica in all probands."
      explanation: >-
        This LHX4 family report supports structural pituitary malformation as
        part of genetic MPHD.
- name: Anterior Pituitary Endocrine-Axis Failure
  description: >-
    Reduced function of multiple anterior pituitary cell lineages causes the
    core endocrine phenotype: GH deficiency, central hypothyroidism, ACTH
    deficiency or central adrenal insufficiency, hypogonadotropic hypogonadism,
    and prolactin deficiency in variable combinations.
  locations:
  - preferred_term: adenohypophysis
    term:
      id: UBERON:0002196
      label: adenohypophysis
  cell_types:
  - preferred_term: somatotroph
    term:
      id: CL:0002312
      label: somatotroph
  - preferred_term: thyrotroph
    term:
      id: CL:0000476
      label: thyrotroph
  - preferred_term: corticotroph
    term:
      id: CL:0002309
      label: corticotroph
  - preferred_term: mammotroph
    term:
      id: CL:0002311
      label: mammotroph
  - preferred_term: gonadotroph
    term:
      id: CL:0000437
      # OAK canonical label is "gonadtroph"; "gonadotroph" is an exact synonym.
      label: gonadtroph
  biological_processes:
  - preferred_term: endocrine process
    term:
      id: GO:0050886
      label: endocrine process
    modifier: DECREASED
  evidence:
  - reference: DOI:10.32641/andespediatr.v94i6.4680
    reference_title: Long-term follow-up data of patients with Multiple Pituitary Hormone Deficiency
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At admission, GH deficiency was found in 88.9% of the cases, TSH deficiency in 77.8%, ACTH deficiency in 33.3%, FSH/LH deficiency in 22.2%, and PRL deficiency in 17.8%."
    explanation: >-
      This cohort quantifies multi-axis anterior pituitary hormone deficiency.
  - reference: DOI:10.1530/ec-24-0217
    reference_title: "Etiology of combined pituitary hormone deficiency: GNAO1 as a novel candidate gene"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of them, 30 had central adrenal insufficiency, 27 had central hypothyroidism, ten had hypogonadotropic hypogonadism, and three had central diabetes insipidus."
    explanation: >-
      This congenital CPHD cohort supports central endocrine-axis failure
      across adrenal, thyroid, gonadal, and posterior pituitary axes.
- name: Structural Pituitary Malformation
  description: >-
    Many genetic CPHD cases have pituitary MRI abnormalities, including
    anterior pituitary hypoplasia, ectopic posterior pituitary, or other
    midline structural defects that correlate with the number of hormone
    deficiencies.
  locations:
  - preferred_term: pituitary gland
    term:
      id: UBERON:0000007
      label: pituitary gland
  - preferred_term: neurohypophysis
    term:
      id: UBERON:0002198
      label: neurohypophysis
  biological_processes:
  - preferred_term: pituitary gland development
    term:
      id: GO:0021983
      label: pituitary gland development
    modifier: ABNORMAL
  evidence:
  - reference: DOI:10.6065/apem.2448008.004
    reference_title: "Clinical and genetic features of childhood-onset congenital combined pituitary hormone deficiency: a retrospective, single-center cohort study"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Brain MRI abnormalities correlated with a higher number of hormone deficiencies (P for trend 0.049) and were present in 33 patients (80.5%)."
    explanation: >-
      This supports structural pituitary or brain MRI abnormalities as common
      and clinically meaningful in congenital CPHD.
phenotypes:
- category: Clinical
  name: Anterior Hypopituitarism
  description: >-
    Deficiency of multiple anterior pituitary hormones is the diagnostic
    endocrine pattern for genetic CPHD.
  phenotype_term:
    preferred_term: anterior hypopituitarism
    term:
      id: HP:0000830
      label: Anterior hypopituitarism
  diagnostic: true
  evidence:
  - reference: DOI:10.32641/andespediatr.v94i6.4680
    reference_title: Long-term follow-up data of patients with Multiple Pituitary Hormone Deficiency
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The deficiency of two or more pituitary hormones is called multiple pituitary hormone deficiencies (MPHD)."
    explanation: >-
      This definition supports anterior hypopituitarism as the core disease
      phenotype when multiple pituitary axes are deficient.
- category: Clinical
  name: Secondary Growth Hormone Deficiency
  description: >-
    GH deficiency is usually prominent and may be the first recognized
    endocrine deficit, causing growth failure or short stature.
  phenotype_term:
    preferred_term: secondary growth hormone deficiency
    term:
      id: HP:0008240
      label: Secondary growth hormone deficiency
  diagnostic: true
  evidence:
  - reference: DOI:10.6065/apem.2448008.004
    reference_title: "Clinical and genetic features of childhood-onset congenital combined pituitary hormone deficiency: a retrospective, single-center cohort study"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Growth hormone deficiency (GHD) was prevalent in 42 (97.7%), and 33 (76.7%) had 3 or more hormone deficiencies."
    explanation: >-
      The congenital CPHD cohort reports GH deficiency in nearly all affected
      patients.
- category: Clinical
  name: Central Hypothyroidism
  description: >-
    Thyrotroph or central TSH-axis failure can cause low thyroid hormone
    production as one component of combined pituitary hormone deficiency.
  phenotype_term:
    preferred_term: central hypothyroidism
    term:
      id: HP:0011787
      label: Central hypothyroidism
  diagnostic: true
  evidence:
  - reference: DOI:10.1530/ec-24-0217
    reference_title: "Etiology of combined pituitary hormone deficiency: GNAO1 as a novel candidate gene"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of them, 30 had central adrenal insufficiency, 27 had central hypothyroidism, ten had hypogonadotropic hypogonadism, and three had central diabetes insipidus."
    explanation: >-
      This cohort directly reports central hypothyroidism in congenital CPHD.
- category: Clinical
  name: Adrenocorticotropic Hormone Deficiency
  description: >-
    ACTH deficiency or central adrenal insufficiency can occur and is clinically
    important because missed adrenal insufficiency can lead to hypoglycemia or
    adrenal crisis during illness.
  phenotype_term:
    preferred_term: adrenocorticotropic hormone deficiency
    term:
      id: HP:0011748
      label: Adrenocorticotropic hormone deficiency
  evidence:
  - reference: DOI:10.32641/andespediatr.v94i6.4680
    reference_title: Long-term follow-up data of patients with Multiple Pituitary Hormone Deficiency
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At admission, GH deficiency was found in 88.9% of the cases, TSH deficiency in 77.8%, ACTH deficiency in 33.3%, FSH/LH deficiency in 22.2%, and PRL deficiency in 17.8%."
    explanation: >-
      This MPHD cohort reports ACTH deficiency among affected patients.
- category: Clinical
  name: Hypogonadotropic Hypogonadism
  description: >-
    Gonadotropin deficiency can produce delayed, absent, or incomplete pubertal
    development and may also contribute to neonatal genital findings in males.
  phenotype_term:
    preferred_term: hypogonadotropic hypogonadism
    term:
      id: HP:0000044
      label: Hypogonadotropic hypogonadism
  evidence:
  - reference: DOI:10.1530/ec-24-0217
    reference_title: "Etiology of combined pituitary hormone deficiency: GNAO1 as a novel candidate gene"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of them, 30 had central adrenal insufficiency, 27 had central hypothyroidism, ten had hypogonadotropic hypogonadism, and three had central diabetes insipidus."
    explanation: >-
      This congenital CPHD cohort directly reports hypogonadotropic
      hypogonadism.
- category: Clinical
  name: Central Diabetes Insipidus
  description: >-
    Posterior pituitary or hypothalamic involvement can produce central
    diabetes insipidus in a minority of congenital CPHD cases.
  phenotype_term:
    preferred_term: central diabetes insipidus
    term:
      id: HP:0000863
      label: Central diabetes insipidus
  evidence:
  - reference: DOI:10.1530/ec-24-0217
    reference_title: "Etiology of combined pituitary hormone deficiency: GNAO1 as a novel candidate gene"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of them, 30 had central adrenal insufficiency, 27 had central hypothyroidism, ten had hypogonadotropic hypogonadism, and three had central diabetes insipidus."
    explanation: >-
      This congenital CPHD cohort reports central diabetes insipidus as one of
      the observed hormone-deficiency phenotypes.
- category: Clinical
  name: Prolactin Deficiency
  description: >-
    Lactotroph-axis involvement can reduce circulating prolactin as part of
    multi-axis anterior pituitary hormone deficiency.
  phenotype_term:
    preferred_term: prolactin deficiency
    term:
      id: HP:0008202
      label: Reduced circulating prolactin concentration
  evidence:
  - reference: DOI:10.32641/andespediatr.v94i6.4680
    reference_title: Long-term follow-up data of patients with Multiple Pituitary Hormone Deficiency
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At admission, GH deficiency was found in 88.9% of the cases, TSH deficiency in 77.8%, ACTH deficiency in 33.3%, FSH/LH deficiency in 22.2%, and PRL deficiency in 17.8%."
    explanation: >-
      This MPHD cohort reports PRL deficiency as one component of the
      multi-axis endocrine phenotype.
- category: Clinical
  name: Short Stature
  description: >-
    Short stature and impaired linear growth are common presenting findings,
    reflecting early GH deficiency.
  phenotype_term:
    preferred_term: short stature
    term:
      id: HP:0004322
      label: Short stature
  evidence:
  - reference: DOI:10.6065/apem.2448008.004
    reference_title: "Clinical and genetic features of childhood-onset congenital combined pituitary hormone deficiency: a retrospective, single-center cohort study"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Short stature was the most frequent (37.2%) initial presentation, and mean height z-score was -2.4."
    explanation: >-
      This cohort identifies short stature as the most frequent initial
      presentation.
- category: Clinical
  name: Neonatal Hypoglycemia
  description: >-
    Neonatal hypoglycemia can be an early clue to congenital GH deficiency and
    combined pituitary hormone deficiency.
  phenotype_term:
    preferred_term: neonatal hypoglycemia
    term:
      id: HP:0001998
      label: Neonatal hypoglycemia
    onset:
      onset_category: NEONATAL
  evidence:
  - reference: DOI:10.3390/ijms241210114
    reference_title: "Management of Neonatal Isolated and Combined Growth Hormone Deficiency: Current Status"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The many clinical signs and symptoms include hypoglycaemia, neonatal cholestasis and micropenis."
    explanation: >-
      This neonatal GHD/combined GHD review lists hypoglycemia among clinical
      signs and symptoms.
- category: Clinical
  name: Neonatal Cholestasis
  description: >-
    Cholestasis may appear during the neonatal presentation of congenital GHD
    or combined pituitary hormone deficiency.
  phenotype_term:
    preferred_term: neonatal cholestasis
    term:
      id: HP:0001396
      label: Cholestasis
    onset:
      onset_category: NEONATAL
  evidence:
  - reference: DOI:10.3390/ijms241210114
    reference_title: "Management of Neonatal Isolated and Combined Growth Hormone Deficiency: Current Status"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The many clinical signs and symptoms include hypoglycaemia, neonatal cholestasis and micropenis."
    explanation: >-
      The review lists neonatal cholestasis among clinical signs and symptoms
      of neonatal isolated and combined GHD.
- category: Clinical
  name: Micropenis
  description: >-
    Micropenis can be a neonatal clue to disrupted hypothalamic-pituitary-gonadal
    axis function in male infants.
  phenotype_term:
    preferred_term: micropenis
    term:
      id: HP:0000054
      label: Micropenis
    onset:
      onset_category: NEONATAL
  evidence:
  - reference: DOI:10.3390/ijms241210114
    reference_title: "Management of Neonatal Isolated and Combined Growth Hormone Deficiency: Current Status"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The many clinical signs and symptoms include hypoglycaemia, neonatal cholestasis and micropenis."
    explanation: >-
      The neonatal management review lists micropenis among signs and symptoms.
- category: Imaging
  name: Anterior Pituitary Hypoplasia
  description: >-
    Anterior pituitary hypoplasia is a structural MRI phenotype reported in
    genetic CPHD and can accompany multiple anterior pituitary hormone deficits.
  phenotype_term:
    preferred_term: anterior pituitary hypoplasia
    term:
      id: HP:0010627
      label: Anterior pituitary hypoplasia
  evidence:
  - reference: DOI:10.3390/ijms26062406
    reference_title: Identification of POU1F1 Variants in Vietnamese Patients with Combined Pituitary Hormone Deficiency
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All six patients exhibited anterior pituitary hypoplasia on brain magnetic resonance imaging and presented with TSH, GH, and PRL deficiencies."
    explanation: >-
      This POU1F1 cohort directly links anterior pituitary hypoplasia with
      combined anterior pituitary hormone deficiencies.
- category: Imaging
  name: Ectopic Posterior Pituitary
  description: >-
    Ectopic posterior pituitary can occur in syndromic or structural forms of
    genetic MPHD.
  phenotype_term:
    preferred_term: ectopic posterior pituitary
    term:
      id: HP:0011755
      label: Ectopic posterior pituitary
  evidence:
  - reference: DOI:10.3390/children12030364
    reference_title: A Novel Missense Variant in LHX4 in Three Children with Multiple Pituitary Hormone Deficiency Belonging to Two Unrelated Families and Contribution of Additional GLI2 and IGFR1 Variant
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Brain magnetic resonance imaging (MRI) revealed pituitary hypoplasia, ectopic posterior pituitary gland, and small sella turcica in all probands."
    explanation: >-
      This LHX4 report directly describes ectopic posterior pituitary in MPHD
      probands.
- category: Imaging
  name: Interrupted Pituitary Stalk
  description: >-
    Pituitary stalk interruption can occur as a structural MRI finding in
    genetic CPHD, including PROP1-associated CPHD with posterior lobe ectopy.
  phenotype_term:
    preferred_term: interrupted pituitary stalk
    term:
      id: HP:0034978
      label: Interrupted pituitary stalk
  evidence:
  - reference: DOI:10.1007/s42000-023-00510-1
    reference_title: Comparison of clinical characteristics of a pediatric cohort with combined pituitary hormone deficiency caused by mutation of the PROP1 gene or of other origins
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MRI of the pituitary gland in CPHD-PROP1 revealed a small pituitary gland (21 cases), pituitary gland enlargement (eight cases), and one pituitary stalk interruption and posterior lobe ectopy, while it was normal in nine cases."
    explanation: >-
      This PROP1 CPHD cohort describes pituitary stalk interruption and
      posterior lobe ectopy among MRI findings.
genetic:
- name: Heterogeneous developmental gene variants
  relationship_type: CAUSATIVE
  presence: Present
  features: >-
    Genetic CPHD can be caused by pathogenic variants across several
    developmental genes. Cohorts identify variants in canonical pituitary genes
    and candidate genes, but a substantial fraction remains genetically
    unsolved.
  evidence:
  - reference: DOI:10.6065/apem.2448008.004
    reference_title: "Clinical and genetic features of childhood-onset congenital combined pituitary hormone deficiency: a retrospective, single-center cohort study"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pathogenic variants in POU1F1, GLI2, HESX1, TBC1D32, and ROBO1 were found in 5 (19.2%)."
    explanation: >-
      This congenital CPHD cohort identifies pathogenic variants in multiple
      developmental genes.
  - reference: DOI:10.1530/ec-24-0217
    reference_title: "Etiology of combined pituitary hormone deficiency: GNAO1 as a novel candidate gene"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The remaining 6 children had causative genetic variants in the GLI2, PROP1, POU1F1, TBX3, PMM2, and GNAO1 genes, respectively."
    explanation: >-
      This independent congenital CPHD cohort supports a heterogeneous causal
      gene spectrum including PROP1, POU1F1, GLI2, and candidate genes.
- name: PROP1 pathogenic variants
  relationship_type: CAUSATIVE
  presence: Present
  gene_term:
    preferred_term: PROP1
    term:
      id: hgnc:9455
      label: PROP1
  inheritance:
  - name: Autosomal recessive inheritance
    inheritance_term:
      preferred_term: autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
  features: >-
    PROP1-associated CPHD is typically autosomal recessive and can involve GH,
    TSH, LH/FSH, prolactin, and later ACTH axes. Pediatric PROP1 cohorts show a
    distinct genotype-phenotype pattern, including lower prolactin, reported
    lower neonatal hypoglycemia frequency than non-PROP1 CPHD, less frequent
    and later secondary adrenal insufficiency, and variable pituitary MRI
    findings.
  evidence:
  - reference: DOI:10.1007/s42000-023-00510-1
    reference_title: Comparison of clinical characteristics of a pediatric cohort with combined pituitary hormone deficiency caused by mutation of the PROP1 gene or of other origins
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most commonly identified genetic cause of combined pituitary hormone deficiency (CPHD) is\n                      PROP1\n                      gene mutations."
    explanation: >-
      This PROP1-focused pediatric cohort identifies PROP1 mutations as the
      most commonly identified genetic cause of CPHD.
  - reference: DOI:10.1530/ec-24-0217
    reference_title: "Etiology of combined pituitary hormone deficiency: GNAO1 as a novel candidate gene"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The remaining 6 children had causative genetic variants in the GLI2, PROP1, POU1F1, TBX3, PMM2, and GNAO1 genes, respectively."
    explanation: >-
      This congenital CPHD cohort includes a child with causative PROP1
      variants among genetically solved cases.
  - reference: DOI:10.1007/s42000-023-00510-1
    reference_title: Comparison of clinical characteristics of a pediatric cohort with combined pituitary hormone deficiency caused by mutation of the PROP1 gene or of other origins
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "significantly lower prolactin concentrations (128 vs. 416.3"
    explanation: >-
      This comparison supports lower prolactin as a PROP1-associated
      genotype-phenotype feature.
  - reference: DOI:10.1007/s42000-023-00510-1
    reference_title: Comparison of clinical characteristics of a pediatric cohort with combined pituitary hormone deficiency caused by mutation of the PROP1 gene or of other origins
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Secondary adrenal insufficiency was less frequent in CPHD-PROP1 (20 vs. 25 cases,"
    explanation: >-
      This comparison supports distinct adrenal-axis involvement in
      PROP1-associated CPHD.
  - reference: DOI:10.1007/s42000-023-00510-1
    reference_title: Comparison of clinical characteristics of a pediatric cohort with combined pituitary hormone deficiency caused by mutation of the PROP1 gene or of other origins
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MRI of the pituitary gland in CPHD-PROP1 revealed a small pituitary gland (21 cases), pituitary gland enlargement (eight cases), and one pituitary stalk interruption and posterior lobe ectopy, while it was normal in nine cases."
    explanation: >-
      This supports variable pituitary MRI findings in PROP1-associated CPHD.
- name: POU1F1 pathogenic variants
  relationship_type: CAUSATIVE
  presence: Present
  gene_term:
    preferred_term: POU1F1
    term:
      id: hgnc:9210
      label: POU1F1
  features: >-
    POU1F1-associated CPHD primarily affects GH, TSH, and prolactin axes and
    can present with anterior pituitary hypoplasia.
  evidence:
  - reference: DOI:10.3390/ijms26062406
    reference_title: Identification of POU1F1 Variants in Vietnamese Patients with Combined Pituitary Hormone Deficiency
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Variants in the POU1F1 gene are associated with combined pituitary hormone deficiency 1 (CPHD1), which manifests as deficiencies in growth hormone (GH), thyroid-stimulating hormone (TSH), and prolactin (PRL)."
    explanation: >-
      This directly identifies POU1F1 variants as a cause of CPHD1 and names
      the affected hormone axes.
  - reference: DOI:10.3390/ijms26062406
    reference_title: Identification of POU1F1 Variants in Vietnamese Patients with Combined Pituitary Hormone Deficiency
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All patients were definitively diagnosed with CPHD1 caused by POU1F1 variants."
    explanation: >-
      This confirms causal POU1F1 diagnoses in the reported Vietnamese CPHD1
      patients.
- name: LHX4 pathogenic variants
  relationship_type: CAUSATIVE
  presence: Present
  gene_term:
    preferred_term: LHX4
    term:
      id: hgnc:21734
      label: LHX4
  inheritance:
  - name: Autosomal dominant heterozygous LHX4-related MPHD
    inheritance_term:
      preferred_term: autosomal dominant inheritance
      term:
        id: HP:0000006
        label: Autosomal dominant inheritance
  features: >-
    Heterozygous LHX4 pathogenic variants can cause MPHD with variable
    expressivity and pituitary structural abnormalities.
  evidence:
  - reference: DOI:10.3390/children12030364
    reference_title: A Novel Missense Variant in LHX4 in Three Children with Multiple Pituitary Hormone Deficiency Belonging to Two Unrelated Families and Contribution of Additional GLI2 and IGFR1 Variant
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This study confirms that heterozygous pathogenic variants of LHX4 can cause MPHD associated with a specific neuroradiological triad of abnormalities despite incomplete penetrance and variable phenotype."
    explanation: >-
      This supports heterozygous LHX4 pathogenic variants as a cause of MPHD
      with variable phenotype.
diagnosis:
- name: Pituitary hormone axis testing
  description: >-
    Diagnostic evaluation requires endocrine testing across GH, thyroid,
    adrenal, gonadal, prolactin, and posterior pituitary axes, with repeated
    follow-up because additional deficits may emerge.
  evidence:
  - reference: DOI:10.3390/jcm13206161
    reference_title: "An Update on Advances in Hypopituitarism: Etiology, Diagnosis, and Current Management"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Diagnosis is based on clinical evaluation and hormonal testing, with identification of the specific hormonal deficiencies essential for effective treatment."
    explanation: >-
      This hypopituitarism review supports clinical and hormonal testing as the
      diagnostic basis.
  - reference: DOI:10.3390/ijms241210114
    reference_title: "Management of Neonatal Isolated and Combined Growth Hormone Deficiency: Current Status"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Diagnosis should be made by laboratory analyses of the growth hormone and other pituitary hormones, rather than by cranial imaging with magnetic resonance imaging."
    explanation: >-
      This neonatal GHD/combined GHD review emphasizes laboratory hormone-axis
      assessment over MRI alone.
- name: Brain and pituitary MRI
  description: >-
    MRI helps document anterior pituitary hypoplasia, ectopic posterior
    pituitary, pituitary stalk interruption patterns, or other midline
    structural abnormalities that refine genetic CPHD risk and surveillance.
  evidence:
  - reference: DOI:10.6065/apem.2448008.004
    reference_title: "Clinical and genetic features of childhood-onset congenital combined pituitary hormone deficiency: a retrospective, single-center cohort study"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Brain MRI abnormalities correlated with a higher number of hormone deficiencies (P for trend 0.049) and were present in 33 patients (80.5%)."
    explanation: >-
      This cohort supports MRI as clinically informative for congenital CPHD.
- name: Genetic testing
  description: >-
    Targeted gene panels, exome sequencing, and family segregation testing can
    identify pathogenic variants, although diagnostic yield remains incomplete.
  evidence:
  - reference: DOI:10.6065/apem.2448008.004
    reference_title: "Clinical and genetic features of childhood-onset congenital combined pituitary hormone deficiency: a retrospective, single-center cohort study"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genetic analyses were performed on 26 patients using a targeted gene panel or whole exome sequencing."
    explanation: >-
      This describes practical targeted-panel and exome approaches in a
      congenital CPHD cohort.
  - reference: DOI:10.1530/ec-24-0217
    reference_title: "Etiology of combined pituitary hormone deficiency: GNAO1 as a novel candidate gene"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genetic etiology was confirmed in 7/34 (21%) children."
    explanation: >-
      This provides a cohort-level genetic diagnostic yield for congenital
      CPHD.
treatments:
- name: Pituitary Hormone Replacement
  description: >-
    Treatment is tailored to the deficient axes and generally consists of
    replacement of missing pituitary target hormones, with attention to
    interactions between replacement therapies.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: Anterior Pituitary Endocrine-Axis Failure
    treatment_effect: MODULATES
    description: >-
      Replacement therapy bypasses deficient endogenous pituitary-axis hormone
      output and treats downstream endocrine failure.
  evidence:
  - reference: DOI:10.3390/jcm13206161
    reference_title: "An Update on Advances in Hypopituitarism: Etiology, Diagnosis, and Current Management"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hormone replacement therapy is the mainstay of treatment, significantly improving patients’ quality of life."
    explanation: >-
      This review supports hormone replacement as the main treatment for
      hypopituitarism.
- name: Human Growth Hormone Replacement Therapy
  description: >-
    Recombinant human growth hormone is used for GH deficiency to reduce
    hypoglycemia risk in early disease and improve growth outcomes.
  treatment_term:
    preferred_term: human growth hormone replacement therapy
    term:
      id: MAXO:0000780
      label: human growth hormone replacement therapy
  target_phenotypes:
  - preferred_term: secondary growth hormone deficiency
    term:
      id: HP:0008240
      label: Secondary growth hormone deficiency
  evidence:
  - reference: DOI:10.3390/ijms241210114
    reference_title: "Management of Neonatal Isolated and Combined Growth Hormone Deficiency: Current Status"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Early GH replacement therapy leads to more positive outcomes, including reduced hypoglycaemia, growth recovery, metabolic asset, and neurodevelopmental improvements."
    explanation: >-
      This neonatal review supports early GH replacement for clinical outcome
      improvement.
  - reference: DOI:10.3390/ijms26062406
    reference_title: Identification of POU1F1 Variants in Vietnamese Patients with Combined Pituitary Hormone Deficiency
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All patients received levothyroxine and recombinant human growth hormone (rhGH) replacement therapy, leading to considerable growth."
    explanation: >-
      This POU1F1 cohort reports rhGH therapy and growth response in CPHD1.
- name: Levothyroxine Replacement
  description: >-
    Levothyroxine is used when central hypothyroidism is present; thyroid-axis
    replacement should be coordinated with adrenal-axis assessment.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: levothyroxine
      term:
        id: CHEBI:6446
        label: levothyroxine sodium anhydrous
  target_phenotypes:
  - preferred_term: central hypothyroidism
    term:
      id: HP:0011787
      label: Central hypothyroidism
  evidence:
  - reference: DOI:10.3390/ijms26062406
    reference_title: Identification of POU1F1 Variants in Vietnamese Patients with Combined Pituitary Hormone Deficiency
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All patients received levothyroxine and recombinant human growth hormone (rhGH) replacement therapy, leading to considerable growth."
    explanation: >-
      This CPHD1 cohort reports levothyroxine use alongside rhGH replacement in
      patients with POU1F1-related CPHD.
- name: Hydrocortisone Replacement
  description: >-
    Hydrocortisone or cortisol glucocorticoid replacement is used when ACTH
    deficiency or central adrenal insufficiency is present, reducing the risk
    from untreated adrenal-axis failure during illness or stress.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: hydrocortisone
      term:
        id: CHEBI:17650
        label: cortisol
  target_phenotypes:
  - preferred_term: adrenocorticotropic hormone deficiency
    term:
      id: HP:0011748
      label: Adrenocorticotropic hormone deficiency
  target_mechanisms:
  - target: Anterior Pituitary Endocrine-Axis Failure
    treatment_effect: MODULATES
    description: >-
      Glucocorticoid replacement bypasses deficient ACTH-driven cortisol
      production downstream of anterior pituitary endocrine-axis failure.
  evidence:
  - reference: DOI:10.1530/ec-24-0217
    reference_title: "Etiology of combined pituitary hormone deficiency: GNAO1 as a novel candidate gene"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of them, 30 had central adrenal insufficiency, 27 had central hypothyroidism, ten had hypogonadotropic hypogonadism, and three had central diabetes insipidus."
    explanation: >-
      This congenital CPHD cohort documents central adrenal insufficiency as a
      frequent target phenotype for glucocorticoid replacement.
  - reference: DOI:10.3390/jcm13206161
    reference_title: "An Update on Advances in Hypopituitarism: Etiology, Diagnosis, and Current Management"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hormone replacement therapy is the mainstay of treatment, significantly improving patients’ quality of life."
    explanation: >-
      This hypopituitarism management review supports hormone replacement as
      the main treatment strategy for deficient pituitary axes.
- name: Desmopressin for Central Diabetes Insipidus
  description: >-
    Desmopressin, a vasopressin analog, is used when posterior pituitary or
    hypothalamic involvement produces central diabetes insipidus.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: desmopressin
      term:
        id: CHEBI:4450
        label: desmopressin
  target_phenotypes:
  - preferred_term: central diabetes insipidus
    term:
      id: HP:0000863
      label: Central diabetes insipidus
  evidence:
  - reference: DOI:10.1530/ec-24-0217
    reference_title: "Etiology of combined pituitary hormone deficiency: GNAO1 as a novel candidate gene"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of them, 30 had central adrenal insufficiency, 27 had central hypothyroidism, ten had hypogonadotropic hypogonadism, and three had central diabetes insipidus."
    explanation: >-
      This congenital CPHD cohort documents central diabetes insipidus as a
      treatment target in a subset of patients.
datasets: []
notes: >-
  Curation was initiated with a minimal page before Falcon research, then
  expanded from the Falcon report and locally fetched reference caches. PubMed
  PMID fetching was attempted but the NCBI DocSum backend returned service
  errors during this run, so evidence references use DOI caches that passed
  local reference validation.
📚

References & Deep Research

Deep Research

1
Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 39 citations 2026-05-10T15:01:10.953148

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Combined Pituitary Hormone Deficiencies, Genetic Form
  • MONDO ID: (if available)
  • Category: Mendelian

Research Objectives

Please provide a comprehensive research report on Combined Pituitary Hormone Deficiencies, Genetic Form covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Combined Pituitary Hormone Deficiencies, Genetic Form (congenital/genetic CPHD/MPHD): Comprehensive Research Report

Target disease and scope

This entry covers congenital/genetic combined pituitary hormone deficiency (CPHD) / multiple pituitary hormone deficiency (MPHD)—a Mendelian/monogenic-leaning but genetically heterogeneous set of disorders characterized by deficiency of ≥2 pituitary hormones, typically beginning in infancy/childhood and sometimes accompanied by midline brain/pituitary structural anomalies and extrapituitary syndromic features. Evidence below is primarily from aggregated disease-level resources (reviews, cohorts) and individual/family case-based genetic discovery studies rather than EHR-only phenotyping. (lee2024clinicalandgenetic pages 1-2, plachy2024etiologyofcombined pages 2-3)

Key identifiers (limitations)

  • MONDO ID: not retrieved in the accessible full texts used here.
  • Orphanet/ORPHA ID: not retrieved in the accessible full texts used here.
  • OMIM identifiers: gene-level OMIM IDs are referenced in some sources, but comprehensive OMIM disease-number crosswalks for “CPHD genetic form” were not extractable from the retrieved evidence corpus.
  • ICD-10/ICD-11 / MeSH: not retrieved in the accessible full texts used here.

Common synonyms and alternative names

  • Combined pituitary hormone deficiency (CPHD) (plachy2024etiologyofcombined pages 2-3, lee2024clinicalandgenetic pages 1-2)
  • Congenital combined pituitary hormone deficiency (cCPHD) (lee2024clinicalandgenetic pages 1-2)
  • Multiple pituitary hormone deficiency (MPHD) (tuz2023longtermfollowupdata pages 9-9, santoro2025anovelmissense pages 1-2)
  • Congenital hypopituitarism (CH) / congenital hypopituitarism with CPHD (aguilarriera2025progressionfromisolated pages 1-2, martinezmayer2024knockoutmicewith pages 1-2)
  • Pituitary stalk interruption syndrome (PSIS) is a frequent radiologic syndrome overlapping with congenital hypopituitarism/CPHD rather than a synonym (lee2024clinicalandgenetic pages 1-2)

1) Disease information (overview; current understanding)

Definition (clinical concept): * A 2024 Korean cohort defines cCPHD as “the nonacquired deficiency of more than one hormone produced by the anterior pituitary gland or released from the posterior pituitary gland.” (Lee et al., Ann Pediatr Endocrinol Metab, 2024-12, https://doi.org/10.6065/apem.2448008.004) (lee2024clinicalandgenetic pages 1-2) * A 2024 Czech cohort operationalizes congenital CPHD as “GHD associated with a deficit of at least one other pituitary hormone”, providing explicit biochemical cutoffs for several axes. (Plachy et al., Endocrine Connections, 2024-07, https://doi.org/10.1530/ec-24-0217) (plachy2024etiologyofcombined pages 2-3)

Diagnostic framing: Genetic CPHD is not a single-gene disease; it is a spectrum caused by disruption of pituitary/hypothalamic development genes and, in some cases, broader syndromic genes. A 2024 Genome Medicine study notes: “Variants in 67 genes are associated with CH, but a vast majority of CH cases lack a genetic diagnosis.” (Martinez‑Mayer et al., Genome Medicine, 2024-05, https://doi.org/10.1186/s13073-024-01347-y) (martinezmayer2024knockoutmicewith pages 1-2)

2) Etiology

2.1 Disease causal factors

Primary causal factor: germline genetic variants impacting hypothalamo–pituitary development, pituitary lineage specification, or hypothalamic signaling; less often chromosomal abnormalities (e.g., microdeletions). (plachy2024etiologyofcombined pages 2-3)

Operational etiologic categories used clinically: 1) Transcription factor/lineage genes (e.g., PROP1, POU1F1, HESX1, LHX3/LHX4) (nguyen2025identificationofpou1f1 pages 2-4, lee2024clinicalandgenetic pages 1-2) 2) Signaling / morphogen pathway genes (e.g., GLI2/SHH-related, FGFR1/FGF8-related) often with midline anomalies (arzilli2025diagnosticchallengesof pages 7-8, arzilli2025diagnosticchallengesof pages 8-10) 3) Chromatin/epigenetic regulators and other pathways (newer) revealed by mouse-to-human discovery (e.g., SETD5, MORC2) (martinezmayer2024knockoutmicewith pages 15-17) 4) Chromosomal CNVs/microdeletions can underlie some congenital hypopituitarism presentations (example: 14q microdeletion involving OTX2) (plachy2024etiologyofcombined pages 1-2)

2.2 Risk factors

Genetic/familial risk: family history, consanguinity, and known pathogenic variants in CPHD genes. Some genes show incomplete penetrance and oligogenicity in congenital pituitary malformations (e.g., GLI2 variants inherited from unaffected parents) (santoro2025anovelmissense pages 1-2).

Non-genetic risk factors: For the specifically genetic form, robust environmental risk factors are not well-established in the evidence retrieved here.

2.3 Protective factors and gene–environment interactions

No protective alleles or gene–environment interactions were directly extractable from the retrieved corpus.

3) Phenotypes (clinical spectrum; HPO suggestions)

3.1 Core endocrine phenotypes

Most individuals have GH deficiency as a prominent or earliest deficit; additional deficits accumulate variably.

Korean congenital CPHD cohort (n=43): * GHD: 42/43 (97.7%) (lee2024clinicalandgenetic pages 1-2) * ≥3 hormone deficiencies: 33/43 (76.7%) (lee2024clinicalandgenetic pages 1-2) * Extrapituitary phenotypes: 31/43 (72.1%) (lee2024clinicalandgenetic pages 1-2)

Long-term MPHD cohort (n=45; admission frequencies): * GH deficiency 88.9%, TSH deficiency 77.8%, ACTH deficiency 33.3%, FSH/LH deficiency 22.2%, PRL deficiency 17.8%; and 62% developed additional deficits during follow-up. (Tuz et al., Andes Pediatrica, 2023-12, https://doi.org/10.32641/andespediatr.v94i6.4680) (tuz2023longtermfollowupdata pages 9-9)

HPO term suggestions (non-exhaustive): * Growth hormone deficiency: HP:0000824 * Central hypothyroidism: HP:0000852 * Secondary adrenal insufficiency (ACTH deficiency): HP:0000846 * Hypogonadotropic hypogonadism: HP:0000044 * Prolactin deficiency / hypoprolactinemia: HP:0000934 (often catalogued as hypoprolactinemia) * Diabetes insipidus (central): HP:0000869

3.2 Presenting features and age of onset

  • In Lee et al. 2024, the mean age at diagnosis was 3.2 years and 41.9% were diagnosed at <1 year. Short stature was the most frequent initial presentation (37.2%), but >50% had neonatal features suggestive of hypopituitarism. (lee2024clinicalandgenetic pages 1-2)

HPO suggestions for neonatal presentations: * Neonatal hypoglycemia: HP:0001998 (supported as a neonatal feature in congenital GHD/CPHD reviews) (stagi2023managementofneonatal pages 10-11) * Micropenis: HP:0000054 (stagi2023managementofneonatal pages 10-11) * Neonatal cholestasis: HP:0006550 (stagi2023managementofneonatal pages 10-11)

3.3 MRI/neuroanatomical phenotypes

  • Lee et al. 2024 reports brain MRI abnormalities in 80.5% of congenital cases, correlating with more hormone deficiencies. (lee2024clinicalandgenetic pages 1-2)
  • PSIS definition: “a combination of hypoplasia or aplasia of the anterior pituitary gland, ectopic pituitary gland, and a thin stalk.” (lee2024clinicalandgenetic pages 1-2)

HPO suggestions: * Pituitary hypoplasia: HP:0000835 * Ectopic posterior pituitary: HP:0006827 * Absent/thin pituitary stalk: HP:0000866 * Septo-optic dysplasia: HP:0000600

3.4 Quality-of-life (QoL)

Direct disease-specific QoL measures for congenital genetic CPHD were not extractable in the retrieved evidence. However, updated clinical reviews emphasize that appropriate hormone replacement “significantly” improves QoL in hypopituitarism broadly. (Iglesias 2024) (iglesias2024anupdateon pages 15-16)

4) Genetic / molecular information

4.1 Causal genes (high-level)

Known gene set size: Martinez‑Mayer et al. (2024) states 67 genes associated with congenital hypopituitarism as of 2023. (martinezmayer2024knockoutmicewith pages 1-2)

Examples of repeatedly implicated CPHD genes (not exhaustive): * PROP1, POU1F1, HESX1, LHX3, LHX4, OTX2, GLI2, SOX3 (nguyen2025identificationofpou1f1 pages 2-4) * Additional candidates and broader etiologic gene lists for CPHD/CH include genes in cilia, axon guidance, chromatin regulation, and hypothalamic signaling (arzilli2025diagnosticchallengesof pages 8-10, martinezmayer2024knockoutmicewith pages 10-12).

A visual gene compendium is available in Martinez‑Mayer et al. 2024 Table 1 (≈70 genes) listing “Human genes implicated in hypothalamic-pituitary abnormalities.” (martinezmayer2024knockoutmicewith media 20fb156a, martinezmayer2024knockoutmicewith media 13ff31db, martinezmayer2024knockoutmicewith media 471988ef, martinezmayer2024knockoutmicewith media 9f0cb61f)

4.2 Inheritance patterns

Inheritance is gene-dependent: * POU1F1 can be autosomal dominant (heterozygous) or autosomal recessive (biallelic): Nguyen et al. notes “heterozygous mutations, representing the autosomal dominant form” vs “homozygous or compound heterozygous mutations… inherited in an autosomal recessive manner.” (Nguyen et al., 2025-03, https://doi.org/10.3390/ijms26062406) (nguyen2025identificationofpou1f1 pages 2-4) * PROP1 is typically recessive; a 2024 pediatric cohort provides examples of homozygous and compound heterozygous PROP1 genotypes. (zygmuntgorska2024comparisonofclinical pages 4-6) * GLI2 shows incomplete penetrance in ectopic posterior pituitary / PSIS contexts. (santoro2025anovelmissense pages 1-2)

4.3 Genotype–phenotype correlations (example: PROP1 vs non-PROP1)

A 2024 cohort directly compares PROP1-CPHD with non-PROP1 etiologies: * PROP1 group had lower baseline TSH and markedly lower prolactin (TSH 1.8 vs 2.4 µIU/mL; PRL 128 vs 416.3 µIU/mL) and less frequent neonatal hypoglycemia than non-PROP1 (0 vs 16%). (Zygmunt‑Górska et al., Hormones, 2024-12, https://doi.org/10.1007/s42000-023-00510-1) (zygmuntgorska2024comparisonofclinical pages 1-2, zygmuntgorska2024comparisonofclinical pages 4-6) * Secondary adrenal insufficiency was less frequent and later in PROP1 (age 13.4 vs 10.4 years). (zygmuntgorska2024comparisonofclinical pages 1-2) * MRI in PROP1 can be variable (small pituitary, enlargement, occasional stalk interruption/ectopy, or normal). (zygmuntgorska2024comparisonofclinical pages 1-2)

4.4 Variant types and interpretation

CPHD involves diverse variant classes (frameshift, splice, missense, CNVs). In Plachy et al. 2024, variants were evaluated using ACMG standards and a chromosomal aberration (14q microdeletion involving OTX2) was among solved cases. (plachy2024etiologyofcombined pages 1-2)

Population allele frequencies / carrier frequencies: not extractable from the retrieved evidence (gnomAD-level frequencies not available in the corpus).

5) Environmental information

For the genetic form, specific non-genetic environmental contributors are not established in the retrieved evidence.

6) Mechanism / pathophysiology

6.1 Conceptual causal chain (upstream → downstream)

Upstream: germline disruption of pituitary organogenesis and lineage specification genes (transcription factors, signaling, chromatin) → Midstream: abnormal pituitary morphogenesis (hypoplasia, stalk interruption, ectopic posterior pituitary) and/or selective failure of endocrine cell differentiation (somatotroph, thyrotroph, lactotroph, gonadotroph, corticotroph) → Downstream: combined hormone deficits (GH, TSH, ACTH, LH/FSH, PRL ± AVP) → clinical manifestations such as growth failure, neonatal hypoglycemia, micropenis/cryptorchidism, central hypothyroidism, adrenal crisis risk, pubertal failure, and DI.

Evidence for developmental-stage effect: Lee et al. emphasizes that “mutations in the late stages of pituitary development cause only hormonal defects”, whereas earlier perturbations can cause hormonal and extrapituitary defects. (lee2024clinicalandgenetic pages 1-2)

6.2 Newly emphasized pathways (2023–2024 research)

Martinez‑Mayer et al. (2024) used embryonic lethal IMPC/DMDD mouse lines to discover candidate genes and pathways: * Screened 209 knockout lines and found 51 with embryonic pituitary malformations (martinezmayer2024knockoutmicewith pages 4-6) * Found functional enrichment clusters including ciliary function, amino acid metabolism, and epigenetics (martinezmayer2024knockoutmicewith pages 15-17) * Highlighted serine–glycine/one-carbon metabolism genes (e.g., PSAT1/PSPH/GLDC) as newly enriched in candidate sets (martinezmayer2024knockoutmicewith pages 10-12, martinezmayer2024knockoutmicewith pages 18-21)

6.3 GO / CL suggestions

GO Biological Process suggestions: * Pituitary gland development (GO:0021983) * Endocrine pancreas development is not relevant; instead consider endocrine system development (GO:0035270) * Cilium organization (GO:0044782) for cilia-enriched candidate sets (martinezmayer2024knockoutmicewith pages 10-12) * Chromatin organization (GO:0006325) / regulation of transcription (GO:0006355) for epigenetic clusters (martinezmayer2024knockoutmicewith pages 10-12) * Serine biosynthetic process (GO:0006564) / one-carbon metabolic process (GO:0006730) for the metabolic cluster (martinezmayer2024knockoutmicewith pages 18-21)

CL (cell types) suggestions: * Somatotroph (CL:0000826) * Thyrotroph (CL:0002412) * Lactotroph (CL:0000665) * Gonadotroph (CL:0000592) * Corticotroph (CL:0002406)

7) Anatomical structures affected

Primary: pituitary gland (anterior pituitary and posterior pituitary/neurohypophysis) and hypothalamic–pituitary axis (lee2024clinicalandgenetic pages 1-2, plachy2024etiologyofcombined pages 2-3).

UBERON suggestions: * Pituitary gland: UBERON:0000007 * Anterior pituitary: UBERON:0001983 * Posterior pituitary: UBERON:0001984 * Hypothalamus: UBERON:0001898

Subcellular (GO CC) suggestions (mechanism-dependent): primary cilium (GO:0005929) for cilia-associated candidate mechanisms (martinezmayer2024knockoutmicewith pages 10-12).

8) Temporal development

Onset: often congenital/neonatal or early childhood. In Lee et al. 2024, ~42% diagnosed <1 year; >50% had neonatal features but not all were diagnosed in infancy. (lee2024clinicalandgenetic pages 1-2)

Progression: hormone deficits may accrue over time. In Tuz et al. 2023, 62% developed additional deficiencies during follow-up. (tuz2023longtermfollowupdata pages 9-9)

9) Inheritance and population

9.1 Epidemiology

Available estimates (heterogeneous definitions): * CH incidence reported as 1 per 3,000–10,000 live births in a pediatric MRI-abnormality cohort paper (Aguilar‑Riera et al., 2025-07, https://doi.org/10.1186/s12902-025-01980-7). (aguilarriera2025progressionfromisolated pages 1-2) * MPHD prevalence estimated at ~1/8,000 worldwide (Tuz et al., 2023-12). (tuz2023longtermfollowupdata pages 9-9)

9.2 Penetrance/expressivity

Incomplete penetrance is highlighted for some variants (e.g., GLI2) and variable expressivity is common across CPHD genes. (santoro2025anovelmissense pages 1-2)

9.3 Founder effects / carrier frequency / sex ratio

Not extractable from the retrieved evidence.

10) Diagnostics (current practice; real-world implementation)

10.1 Core clinical and biochemical testing

Diagnosis is based on clinical suspicion plus endocrine testing to identify deficient axes. A practical congenital CPHD definition used by Plachy et al. includes: * IGF‑1 <0 SDS and stimulated GH <10 µg/L (their cutoff) (plachy2024etiologyofcombined pages 2-3) * Central hypothyroidism: low free T4 with inappropriately low/normal TSH (plachy2024etiologyofcombined pages 2-3)

LOINC suggestions (examples; local labs differ): * IGF-1 in Serum/Plasma (commonly LOINC 14159-1) * Cortisol (e.g., 2143-6) * Free T4 (e.g., 3024-7) * Prolactin (e.g., 2842-3)

10.2 Imaging

MRI is strongly emphasized when hypopituitarism is documented: “All patients with documented hypopituitarism warrant an MRI.” (Gan et al., 2019, Brook’s Clinical Pediatric Endocrinology, https://doi.org/10.1002/9781119152712.ch5) (gan2019disordersofhypothalamo‐pituitary pages 40-42)

10.3 Genetic testing strategy

Evidence from cohorts indicates modest diagnostic yield even with modern sequencing: * Lee et al. 2024: pathogenic variants in 5/26 tested (19.2%) using targeted panel/WES (lee2024clinicalandgenetic pages 1-2) * Plachy et al. 2024: solved 7/34 (21%) with tiered testing and NGS panel (plachy2024etiologyofcombined pages 1-2) * Review-level statement: Sanger-based approaches historically <15% yield; NGS can increase yield toward ~19% (nguyen2025identificationofpou1f1 pages 2-4)

10.4 Differential diagnosis

Not fully developed in the accessible evidence corpus; in practice includes acquired hypopituitarism, pituitary tumors, infiltrative lesions, traumatic brain injury, and syndromic neurodevelopmental disorders where pituitary deficits are secondary.

11) Outcomes / prognosis

Direct survival estimates for congenital genetic CPHD were not extractable from the retrieved evidence. Available longitudinal cohort evidence emphasizes that: * Additional hormone deficits may develop years after initial diagnosis, necessitating long-term monitoring (tuz2023longtermfollowupdata pages 9-9) * Appropriate replacement mitigates morbidity; neonatal/childhood management focuses on preventing hypoglycemia/adrenal crisis and optimizing growth/development (stagi2023managementofneonatal pages 10-11)

12) Treatment (standard of care; real-world use)

Treatment is predominantly hormone replacement, tailored to which axes are deficient.

12.1 Glucocorticoid replacement (central adrenal insufficiency)

Neonatal/infant management review provides explicit dosing and emergency instructions: * Maintenance hydrocortisone: 9–12 mg/m²/day divided into 3–4 doses (stagi2023managementofneonatal pages 10-11) * Emergency IM hydrocortisone: 25 mg (<1 year), 25–50 mg (1–5 years), 100 mg (>5 years) (stagi2023managementofneonatal pages 10-11)

A broader updated adult hypopituitarism management review also details stress dosing protocols (e.g., high-dose IV regimens in crisis) and notes modified-release hydrocortisone options. (Iglesias 2024-10, https://doi.org/10.3390/jcm13206161) (iglesias2024anupdateon pages 15-16)

Clinical pearl: ACTH deficiency may mask diabetes insipidus until glucocorticoids are started; thus DI can “appear” after starting hydrocortisone, requiring close fluid/electrolyte monitoring. (stagi2023managementofneonatal pages 10-11, gan2019disordersofhypothalamo‐pituitary pages 40-42)

12.2 Thyroid hormone replacement (central hypothyroidism)

Levothyroxine is standard; dosing is titrated by free T4 rather than TSH in central hypothyroidism (gan2019disordersofhypothalamo‐pituitary pages 40-42, iglesias2024anupdateon pages 15-16).

12.3 GH replacement

Early rhGH therapy is emphasized in neonatal/early-life disease: * Proposed neonatal dosing in one review: 25–50 µg/kg/day during the first year (Stagi et al., 2023-06, https://doi.org/10.3390/ijms241210114) (stagi2023managementofneonatal pages 10-11)

Real-world safety/implementation (from cited observational data summarized in a CPHD genetics paper): adverse events reported in 14.4% of treated patients; discontinuation for adverse events 1.6%; common events included headache (0.4%) and scoliosis (0.2%). (nguyen2025identificationofpou1f1 pages 2-4)

12.4 Gonadal axis and micropenis/cryptorchidism (selected cases)

Neonatal androgen therapy options include testosterone IM or topical DHT; orchidopexy ideally by ~18 months for cryptorchidism. (stagi2023managementofneonatal pages 10-11)

12.5 AVP deficiency (central diabetes insipidus)

Desmopressin is used with careful titration and attention to osmolality and thirst/adipsia issues. (gan2019disordersofhypothalamo‐pituitary pages 40-42, iglesias2024anupdateon pages 15-16)

12.6 MAXO suggestions (management actions)

  • Hormone replacement therapy: MAXO:0000058 (general)
  • Growth hormone therapy: MAXO:0000424 (if available in your MAXO version)
  • Hydrocortisone therapy / glucocorticoid replacement: map under hormone replacement
  • Levothyroxine therapy: map under hormone replacement
  • Desmopressin therapy: map under pharmacotherapy
  • Pituitary MRI: map under diagnostic imaging

12.7 Advanced therapeutics / gene therapy

No interventional gene-therapy trials specific to genetic CPHD were identified in the clinical trial search results available here.

13) Prevention

Primary prevention is not established for most genetic CPHD. Secondary/tertiary prevention focuses on: * Early recognition of neonatal features (hypoglycemia, cholestasis, micropenis) and urgent management (stagi2023managementofneonatal pages 10-11, lee2024clinicalandgenetic pages 1-2) * Genetic counseling for families with identified pathogenic variants

14) Other species / natural disease

Not systematically retrievable from the available evidence corpus.

15) Model organisms

Martinez‑Mayer et al. (2024) demonstrates a scalable model-organism approach: screening embryonic lethal/sub-viable mouse knockouts for pituitary malformations. They report 51/209 knockout lines with embryonic pituitary defects and demonstrate translation to human candidates (MORC2 and SETD5). (martinezmayer2024knockoutmicewith pages 4-6, martinezmayer2024knockoutmicewith pages 15-17, martinezmayer2024knockoutmicewith pages 1-2)

Key 2023–2024 developments (prioritized)

1) 2024 cohort quantification of congenital CPHD burden and phenotype: high rates of MRI abnormalities (80.5%), high neonatal feature frequency (53.5%), and frequent extrapituitary phenotypes (72.1%) in a tertiary-center congenital cohort. (Lee 2024) (lee2024clinicalandgenetic pages 1-2) 2) 2024 candidate-gene expansion via IMPC/DMDD mouse phenomics: discovery of 51 pituitary-malformation genes from embryonic lethal screens, highlighting cilia, epigenetic regulation, and serine–glycine metabolism as candidate pathway classes. (Martinez‑Mayer 2024) (martinezmayer2024knockoutmicewith pages 10-12, martinezmayer2024knockoutmicewith pages 4-6) 3) 2024 identification of potential new CPHD candidate gene GNAO1 in a congenital CPHD cohort with ACMG-classified variants and midline MRI defects. (Plachy 2024) (plachy2024etiologyofcombined pages 1-2) 4) 2024 PROP1 vs non-PROP1 phenotype differences that may guide targeted genetic workup and anticipate late ACTH deficiency. (Zygmunt‑Górska 2024) (zygmuntgorska2024comparisonofclinical pages 1-2, zygmuntgorska2024comparisonofclinical pages 4-6)

Evidence synthesis table

Study Year Journal URL Core definition / diagnostic criteria Key genes implicated / inheritance notes Common phenotypes / MRI findings Key epidemiology / diagnostic yield / numeric data Citation
Lee et al. 2024 Annals of Pediatric Endocrinology & Metabolism https://doi.org/10.6065/apem.2448008.004 cCPHD defined as nonacquired deficiency of >1 pituitary hormone; diagnosis anchored to time of first hormone deficiency identification Cohort pathogenic variants in POU1F1, GLI2, HESX1, TBC1D32, ROBO1; developmental-stage concept noted: earlier genes more often syndromic, later genes more often hormone-limited Initial presentation: short stature 37.2%; neonatal hypopituitarism features 53.5%; GHD 97.7%; >=3 hormone deficits 76.7%; extrapituitary phenotypes 72.1%; brain MRI abnormalities 80.5%; PSIS defined as anterior pituitary hypoplasia/aplasia + ectopic posterior pituitary + thin stalk 444 CPHD records screened; 43 congenital cases included; genetic diagnosis in tested subset 5/26 (19.2%); prior literature cited genetic abnormality rate 1.3%–7.3% (lee2024clinicalandgenetic pages 1-2)
Plachy et al. 2024 Endocrine Connections https://doi.org/10.1530/ec-24-0217 CPHD defined as GHD + at least one other pituitary hormone deficit; GHD supported by low IGF-1 and stimulated GH <10 µg/L; central hypothyroidism = low free T4 with inappropriately low/normal TSH; explicit criteria provided for central adrenal insufficiency, HH, and DI Confirmed causes included OTX2 14q microdeletion and variants in GLI2, PROP1, POU1F1, TBX3, PMM2, GNAO1; GNAO1 proposed as novel candidate; inheritance not detailed in excerpt In 34 children: central adrenal insufficiency 30/34; central hypothyroidism 27/34; hypogonadotropic hypogonadism 10/34; central DI 3/34; midline MRI defect 26/34 Genetic etiology solved in 7/34 (21%); authors note reported molecular detection rates across studies 0%–65%; >80% of congenital CPHD cases still lack molecular diagnosis; PROP1 only 1/34 (3%) in this cohort (plachy2024etiologyofcombined pages 1-2, plachy2024etiologyofcombined pages 2-3)
Stagi et al. 2023 International Journal of Molecular Sciences https://doi.org/10.3390/ijms241210114 Review of neonatal isolated/combined GHD; diagnosis should rely on laboratory assessment of GH and other pituitary hormones rather than MRI alone; early replacement emphasized Genes highlighted include HESX1, LHX3, LHX4, SOX2, SOX3, GLI2, OTX2, PROP1, POU1F1; early-development genes more often syndromic, later-stage genes often produce endocrine-only phenotypes Neonatal clues: hypoglycemia, cholestasis, micropenis; cortisol deficiency can mask DI; DI may emerge after glucocorticoid treatment Congenital GHD described as rare and more often part of multiple pituitary hormone deficiency; treatment details include rhGH 25–50 µg/kg/day in first year; hydrocortisone maintenance 9–12 mg/m2/day; emergency IM hydrocortisone: 25 mg (<1 y), 25–50 mg (1–5 y), 100 mg (>5 y) (stagi2023managementofneonatal pages 10-11)
Tuz et al. 2023 Andes Pediatrica https://doi.org/10.32641/andespediatr.v94i6.4680 MPHD defined as deficiency of >=2 pituitary hormones Gene-level data not emphasized in excerpt At admission: GH deficiency 88.9%, TSH deficiency 77.8%, ACTH deficiency 33.3%, FSH/LH deficiency 22.2%, PRL deficiency 17.8%; additional deficits accrued over follow-up Prevalence estimated at ~1/8,000 worldwide; 45 patients; mean age at presentation 5.6 ± 3.9 y; mean follow-up 9.18 ± 3.6 y; 62% developed additional hormonal deficiencies during follow-up (tuz2023longtermfollowupdata pages 9-9)
Aguilar-Riera et al. 2025 BMC Endocrine Disorders https://doi.org/10.1186/s12902-025-01980-7 CH defined as deficiency of one or more pituitary hormones due to fetal developmental events; CPHD = >=2 pituitary deficiencies; GHD in study defined by dynamic GH test <7.4 ng/mL plus short stature context Broad developmental gene list provided: early genes (HESX1, SOX2/3, PITX1/2, OTX2, RAX, LHX3/4, GLI2, PAX6, BMP4, FGFR1 etc.) and later genes (POU1F1, PROP1, GH1, GHRHR, TBX19, POMC etc.); one cohort patient had pathogenic GLI2 variant MRI syndromes/features highlighted: PSIS, septo-optic dysplasia, holoprosencephaly, anterior pituitary hypoplasia; progression from isolated GHD to CPHD documented, with TSH deficiency most frequent additional deficit CH incidence stated as 1 per 3,000–10,000 live births; in cohort, CPHD emerged after about 5 years on average; among those progressing, TSH deficiency 80%, then gonadotropins, with ACTH and AVP less frequent (aguilarriera2025progressionfromisolated pages 1-2)
Nguyen et al. 2025 International Journal of Molecular Sciences https://doi.org/10.3390/ijms26062406 CPHD/MPHD described as disorders where pathogenic variants in pituitary-development genes cause deficiency of one or more pituitary hormones; POU1F1-associated disease often involves GH, PRL, TSH deficits and anterior pituitary hypoplasia States ~70 genes linked to hypopituitarism; PROP1 is most common, accounting for up to 55% of CPHD cases; recurrent genes include POU1F1, HESX1, LHX3, LHX4, OTX2, GLI2, SOX3; POU1F1 may be autosomal dominant (heterozygous) or autosomal recessive (homozygous/compound heterozygous) POU1F1 phenotype: severe short stature, facial dysmorphism, poor feeding in infancy; MRI: anterior pituitary hypoplasia Historical Sanger sequencing yield <15%; next-generation sequencing yield up to 19.1%; ~70 genes implicated overall; adverse events during rhGH treatment reported in 14.4% of patients in cited real-world data (nguyen2025identificationofpou1f1 pages 2-4)
Martinez-Mayer et al. 2024 Genome Medicine https://doi.org/10.1186/s13073-024-01347-y Congenital hypopituitarism/CPHD framed as genetically heterogeneous midline developmental disorder; study used mouse embryonic phenotyping to expand candidate-gene discovery rather than provide clinical diagnostic cutoffs States 67 genes associated with CH by 2023; IMPC/DMDD screen of 209 embryonic lethal/subviable knockout lines identified 51 genes with pituitary malformations; human candidate validation found variants in MORC2 and SETD5; pathways enriched included cilia-related functions, chromatin/epigenetic regulation, and serine-glycine metabolism Mouse malformations included absent, hypoplastic, and dysmorphic anterior/posterior pituitary; candidate pathways suggest mechanisms for human pituitary malformation and syndromic CH/CPHD “Vast majority” of CH cases remain genetically unsolved; 51/209 knockout lines abnormal (~24.4%); among candidate genes, 32/51 (63%) associated with human disease; known CH genes had risen to 67 (martinezmayer2024knockoutmicewith pages 10-12, martinezmayer2024knockoutmicewith pages 15-17, martinezmayer2024knockoutmicewith pages 4-6, martinezmayer2024knockoutmicewith pages 18-21, martinezmayer2024knockoutmicewith pages 1-2)

Table: This table compiles the most useful disease-characteristics evidence for congenital/genetic CPHD/MPHD across recent cohort, review, and discovery studies. It highlights how the disorder is defined, which genes are implicated, what phenotypes and MRI findings are common, and the main epidemiology and diagnostic-yield numbers relevant for a knowledge base.

Visual evidence (gene compendium)

Martinez‑Mayer et al. 2024 provides a curated table of “Human genes implicated in hypothalamic-pituitary abnormalities,” useful as a gene list reference for panels/WES interpretation. (martinezmayer2024knockoutmicewith media 20fb156a, martinezmayer2024knockoutmicewith media 13ff31db)

Evidence gaps (for KB completion)

  • Standardized disease IDs (MONDO/ORPHA/ICD/MeSH) and comprehensive OMIM crosswalks were not retrievable from the accessible full texts in this run.
  • Population genetics (carrier frequencies; founder variants) and disease-specific QoL statistics remain under-captured in the retrieved corpus.
  • Differential diagnosis and standardized diagnostic criteria statements from endocrine society pediatric congenital hypopituitarism guidelines were not fully accessible in the retrieved full texts.

References

  1. (lee2024clinicalandgenetic pages 1-2): Yoonha Lee, Young Ah Lee, Jung Min Ko, Choong Ho Shin, and Yun Jeong Lee. Clinical and genetic features of childhood-onset congenital combined pituitary hormone deficiency: a retrospective, single-center cohort study. Annals of Pediatric Endocrinology & Metabolism, 29:379-386, Dec 2024. URL: https://doi.org/10.6065/apem.2448008.004, doi:10.6065/apem.2448008.004. This article has 6 citations.

  2. (plachy2024etiologyofcombined pages 2-3): Lukas Plachy, Petra Dusatkova, Klara Maratova, Shenali Anne Amaratunga, Dana Zemkova, Vit Neuman, Stanislava Kolouskova, Barbora Obermannova, Marta Snajderova, Zdenek Sumnik, Jan Lebl, and Stepanka Pruhova. Etiology of combined pituitary hormone deficiency: gnao1 as a novel candidate gene. Endocrine Connections, Jul 2024. URL: https://doi.org/10.1530/ec-24-0217, doi:10.1530/ec-24-0217. This article has 1 citations and is from a peer-reviewed journal.

  3. (tuz2023longtermfollowupdata pages 9-9): Aysegul Elvan Tuz, Elvan Bayramoğlu, and Semra Çetinkaya. Long-term follow-up data of patients with multiple pituitary hormone deficiency. Andes Pediatrica, 94:689, Dec 2023. URL: https://doi.org/10.32641/andespediatr.v94i6.4680, doi:10.32641/andespediatr.v94i6.4680. This article has 0 citations.

  4. (santoro2025anovelmissense pages 1-2): Claudia Santoro, Francesca Aiello, Antonella Farina, Emanuele Miraglia del Giudice, Filomena Pascarella, Maria Rosaria Licenziati, Nicola Improda, Giulio Piluso, Annalaura Torella, Francesca Del Vecchio Blanco, Mario Cirillo, Vincenzo Nigro, and Anna Grandone. A novel missense variant in lhx4 in three children with multiple pituitary hormone deficiency belonging to two unrelated families and contribution of additional gli2 and igfr1 variant. Children, 12:364, Mar 2025. URL: https://doi.org/10.3390/children12030364, doi:10.3390/children12030364. This article has 0 citations.

  5. (aguilarriera2025progressionfromisolated pages 1-2): Cristina Aguilar-Riera, Diego Yeste, Núria González-Llorens, Eduard Mogas, Ariadna Campos-Martorell, Paula Fernandez-Alvarez, Elida Vázquez, and María Clemente. Progression from isolated growth hormone deficiency to a combined pituitary hormone deficiency in a cohort of paediatrics patients with pituitary morphology abnormalities on mri. BMC Endocrine Disorders, Jul 2025. URL: https://doi.org/10.1186/s12902-025-01980-7, doi:10.1186/s12902-025-01980-7. This article has 0 citations and is from a peer-reviewed journal.

  6. (martinezmayer2024knockoutmicewith pages 1-2): Julian Martinez-Mayer, Michelle L. Brinkmeier, Sean P. O’Connell, Arnold Ukagwu, Marcelo A. Marti, Mirta Miras, Maria V. Forclaz, Maria G. Benzrihen, Leonard Y. M. Cheung, Sally A. Camper, Buffy S. Ellsworth, Lori T. Raetzman, Maria I. Pérez-Millán, and Shannon W. Davis. Knockout mice with pituitary malformations help identify human cases of hypopituitarism. Genome Medicine, May 2024. URL: https://doi.org/10.1186/s13073-024-01347-y, doi:10.1186/s13073-024-01347-y. This article has 7 citations and is from a highest quality peer-reviewed journal.

  7. (nguyen2025identificationofpou1f1 pages 2-4): Ha Thu Nguyen, Khanh Ngoc Nguyen, Tran Minh Dien, Thi Bich Ngoc Can, Thi Thanh Ngan Nguyen, Nguyen Thi Kim Lien, Nguyen Van Tung, Nguyen Thi Xuan, Nguyen Thien Tao, Ngoc Lan Nguyen, Van Khanh Tran, Tran Thi Chi Mai, Van Anh Tran, Huy Hoang Nguyen, and Chi Dung Vu. Identification of pou1f1 variants in vietnamese patients with combined pituitary hormone deficiency. International Journal of Molecular Sciences, Mar 2025. URL: https://doi.org/10.3390/ijms26062406, doi:10.3390/ijms26062406. This article has 0 citations.

  8. (arzilli2025diagnosticchallengesof pages 7-8): Federica Arzilli, Giulia De Fortuna, Ignazio Cammisa, Luca Vagnozzi, Giorgio Sodero, Donato Rigante, and Clelia Cipolla. Diagnostic challenges of short stature and growth hormone insufficiency across different genetic etiologies. Biomedicines, 13:1937, Aug 2025. URL: https://doi.org/10.3390/biomedicines13081937, doi:10.3390/biomedicines13081937. This article has 4 citations.

  9. (arzilli2025diagnosticchallengesof pages 8-10): Federica Arzilli, Giulia De Fortuna, Ignazio Cammisa, Luca Vagnozzi, Giorgio Sodero, Donato Rigante, and Clelia Cipolla. Diagnostic challenges of short stature and growth hormone insufficiency across different genetic etiologies. Biomedicines, 13:1937, Aug 2025. URL: https://doi.org/10.3390/biomedicines13081937, doi:10.3390/biomedicines13081937. This article has 4 citations.

  10. (martinezmayer2024knockoutmicewith pages 15-17): Julian Martinez-Mayer, Michelle L. Brinkmeier, Sean P. O’Connell, Arnold Ukagwu, Marcelo A. Marti, Mirta Miras, Maria V. Forclaz, Maria G. Benzrihen, Leonard Y. M. Cheung, Sally A. Camper, Buffy S. Ellsworth, Lori T. Raetzman, Maria I. Pérez-Millán, and Shannon W. Davis. Knockout mice with pituitary malformations help identify human cases of hypopituitarism. Genome Medicine, May 2024. URL: https://doi.org/10.1186/s13073-024-01347-y, doi:10.1186/s13073-024-01347-y. This article has 7 citations and is from a highest quality peer-reviewed journal.

  11. (plachy2024etiologyofcombined pages 1-2): Lukas Plachy, Petra Dusatkova, Klara Maratova, Shenali Anne Amaratunga, Dana Zemkova, Vit Neuman, Stanislava Kolouskova, Barbora Obermannova, Marta Snajderova, Zdenek Sumnik, Jan Lebl, and Stepanka Pruhova. Etiology of combined pituitary hormone deficiency: gnao1 as a novel candidate gene. Endocrine Connections, Jul 2024. URL: https://doi.org/10.1530/ec-24-0217, doi:10.1530/ec-24-0217. This article has 1 citations and is from a peer-reviewed journal.

  12. (stagi2023managementofneonatal pages 10-11): Stefano Stagi, Maria Tufano, Nicolò Chiti, Matteo Cerutti, Alessandra Li Pomi, Tommaso Aversa, and Malgorzata Wasniewska. Management of neonatal isolated and combined growth hormone deficiency: current status. International Journal of Molecular Sciences, 24:10114, Jun 2023. URL: https://doi.org/10.3390/ijms241210114, doi:10.3390/ijms241210114. This article has 9 citations.

  13. (iglesias2024anupdateon pages 15-16): Pedro Iglesias. An update on advances in hypopituitarism: etiology, diagnosis, and current management. Journal of Clinical Medicine, 13:6161, Oct 2024. URL: https://doi.org/10.3390/jcm13206161, doi:10.3390/jcm13206161. This article has 33 citations.

  14. (martinezmayer2024knockoutmicewith pages 10-12): Julian Martinez-Mayer, Michelle L. Brinkmeier, Sean P. O’Connell, Arnold Ukagwu, Marcelo A. Marti, Mirta Miras, Maria V. Forclaz, Maria G. Benzrihen, Leonard Y. M. Cheung, Sally A. Camper, Buffy S. Ellsworth, Lori T. Raetzman, Maria I. Pérez-Millán, and Shannon W. Davis. Knockout mice with pituitary malformations help identify human cases of hypopituitarism. Genome Medicine, May 2024. URL: https://doi.org/10.1186/s13073-024-01347-y, doi:10.1186/s13073-024-01347-y. This article has 7 citations and is from a highest quality peer-reviewed journal.

  15. (martinezmayer2024knockoutmicewith media 20fb156a): Julian Martinez-Mayer, Michelle L. Brinkmeier, Sean P. O’Connell, Arnold Ukagwu, Marcelo A. Marti, Mirta Miras, Maria V. Forclaz, Maria G. Benzrihen, Leonard Y. M. Cheung, Sally A. Camper, Buffy S. Ellsworth, Lori T. Raetzman, Maria I. Pérez-Millán, and Shannon W. Davis. Knockout mice with pituitary malformations help identify human cases of hypopituitarism. Genome Medicine, May 2024. URL: https://doi.org/10.1186/s13073-024-01347-y, doi:10.1186/s13073-024-01347-y. This article has 7 citations and is from a highest quality peer-reviewed journal.

  16. (martinezmayer2024knockoutmicewith media 13ff31db): Julian Martinez-Mayer, Michelle L. Brinkmeier, Sean P. O’Connell, Arnold Ukagwu, Marcelo A. Marti, Mirta Miras, Maria V. Forclaz, Maria G. Benzrihen, Leonard Y. M. Cheung, Sally A. Camper, Buffy S. Ellsworth, Lori T. Raetzman, Maria I. Pérez-Millán, and Shannon W. Davis. Knockout mice with pituitary malformations help identify human cases of hypopituitarism. Genome Medicine, May 2024. URL: https://doi.org/10.1186/s13073-024-01347-y, doi:10.1186/s13073-024-01347-y. This article has 7 citations and is from a highest quality peer-reviewed journal.

  17. (martinezmayer2024knockoutmicewith media 471988ef): Julian Martinez-Mayer, Michelle L. Brinkmeier, Sean P. O’Connell, Arnold Ukagwu, Marcelo A. Marti, Mirta Miras, Maria V. Forclaz, Maria G. Benzrihen, Leonard Y. M. Cheung, Sally A. Camper, Buffy S. Ellsworth, Lori T. Raetzman, Maria I. Pérez-Millán, and Shannon W. Davis. Knockout mice with pituitary malformations help identify human cases of hypopituitarism. Genome Medicine, May 2024. URL: https://doi.org/10.1186/s13073-024-01347-y, doi:10.1186/s13073-024-01347-y. This article has 7 citations and is from a highest quality peer-reviewed journal.

  18. (martinezmayer2024knockoutmicewith media 9f0cb61f): Julian Martinez-Mayer, Michelle L. Brinkmeier, Sean P. O’Connell, Arnold Ukagwu, Marcelo A. Marti, Mirta Miras, Maria V. Forclaz, Maria G. Benzrihen, Leonard Y. M. Cheung, Sally A. Camper, Buffy S. Ellsworth, Lori T. Raetzman, Maria I. Pérez-Millán, and Shannon W. Davis. Knockout mice with pituitary malformations help identify human cases of hypopituitarism. Genome Medicine, May 2024. URL: https://doi.org/10.1186/s13073-024-01347-y, doi:10.1186/s13073-024-01347-y. This article has 7 citations and is from a highest quality peer-reviewed journal.

  19. (zygmuntgorska2024comparisonofclinical pages 4-6): Agata Zygmunt-Górska, Małgorzata Wójcik, Aleksandra Gilis-Januszewska, Anna Starmach, Mirosław Bik-Multanowski, and Jerzy B. Starzyk. Comparison of clinical characteristics of a pediatric cohort with combined pituitary hormone deficiency caused by mutation of the prop1 gene or of other origins. Hormones, 23:69-79, Dec 2024. URL: https://doi.org/10.1007/s42000-023-00510-1, doi:10.1007/s42000-023-00510-1. This article has 3 citations and is from a peer-reviewed journal.

  20. (zygmuntgorska2024comparisonofclinical pages 1-2): Agata Zygmunt-Górska, Małgorzata Wójcik, Aleksandra Gilis-Januszewska, Anna Starmach, Mirosław Bik-Multanowski, and Jerzy B. Starzyk. Comparison of clinical characteristics of a pediatric cohort with combined pituitary hormone deficiency caused by mutation of the prop1 gene or of other origins. Hormones, 23:69-79, Dec 2024. URL: https://doi.org/10.1007/s42000-023-00510-1, doi:10.1007/s42000-023-00510-1. This article has 3 citations and is from a peer-reviewed journal.

  21. (martinezmayer2024knockoutmicewith pages 4-6): Julian Martinez-Mayer, Michelle L. Brinkmeier, Sean P. O’Connell, Arnold Ukagwu, Marcelo A. Marti, Mirta Miras, Maria V. Forclaz, Maria G. Benzrihen, Leonard Y. M. Cheung, Sally A. Camper, Buffy S. Ellsworth, Lori T. Raetzman, Maria I. Pérez-Millán, and Shannon W. Davis. Knockout mice with pituitary malformations help identify human cases of hypopituitarism. Genome Medicine, May 2024. URL: https://doi.org/10.1186/s13073-024-01347-y, doi:10.1186/s13073-024-01347-y. This article has 7 citations and is from a highest quality peer-reviewed journal.

  22. (martinezmayer2024knockoutmicewith pages 18-21): Julian Martinez-Mayer, Michelle L. Brinkmeier, Sean P. O’Connell, Arnold Ukagwu, Marcelo A. Marti, Mirta Miras, Maria V. Forclaz, Maria G. Benzrihen, Leonard Y. M. Cheung, Sally A. Camper, Buffy S. Ellsworth, Lori T. Raetzman, Maria I. Pérez-Millán, and Shannon W. Davis. Knockout mice with pituitary malformations help identify human cases of hypopituitarism. Genome Medicine, May 2024. URL: https://doi.org/10.1186/s13073-024-01347-y, doi:10.1186/s13073-024-01347-y. This article has 7 citations and is from a highest quality peer-reviewed journal.

  23. (gan2019disordersofhypothalamo‐pituitary pages 40-42): Hoong‐Wei Gan, Kyriaki‐Sandy Alatzoglou, and Mehul T. Dattani. Disorders of hypothalamo‐pituitary axis. Brook's Clinical Pediatric Endocrinology, pages 133-198, Aug 2019. URL: https://doi.org/10.1002/9781119152712.ch5, doi:10.1002/9781119152712.ch5. This article has 8 citations.